NovaBridge Biosciences (NBP) EPS (Weighted Average and Diluted) (2019 - 2025)

NovaBridge Biosciences (NBP) has 5 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.33 in Q4 2025.

• Quarterly EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.33 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$0.33 (changed N/A YoY) and the FY2025 annual result came in at -$0.21, up 22.22% from the prior year.
• EPS (Weighted Average and Diluted) grew to -$0.33 in Q4 2025 per NBP's latest filing, from -$40164.7 in the prior quarter.
• Across five years, EPS (Weighted Average and Diluted) topped out at $312400.0 in Q2 2024 and bottomed at -$50036.4 in Q2 2025.
• The 3-year median for EPS (Weighted Average and Diluted) is -$1.42 (2023), against an average of $61426.7.
• Peak annual rise in EPS (Weighted Average and Diluted) reached 116.02% in 2025, while the deepest fall reached 127.44% in 2025.
• Tracing NBP's EPS (Weighted Average and Diluted) over 3 years: stood at -$2.51 in 2023, then soared by 5842005.9% to $146364.3 in 2024, then plunged by 100.0% to -$0.33 in 2025.
• Per Business Quant, the three latest NBP EPS (Weighted Average and Diluted) figures stand at -$0.33 (Q4 2025), -$40164.7 (Q3 2025), and -$50036.4 (Q2 2025).

Peer Comparison